Redhill biopharma's RHB-204 granted FDA fast track designation for NTM disease

(RedHill Biopharma) RedHill Biopharma Ltd. (Nasdaq: RDHL), a specialty biopharmaceutical company, today announced that RHB-204 has been granted Fast Track designation by the US Food and Drug Administration (FDA) for its development as a potential first-line, stand-alone, oral treatment of pulmonary nontuberculous mycobacteria (NTM) disease caused by Mycobacterium avium Complex (MAC) -- a rare disease for which there is no FDA-approved first-line therapy.
Source: EurekAlert! - Biology - Category: Biology Source Type: news